Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

50.96 +2.71 (+5.62%)

Official Closing Price Updated: 7:00 PM EST, Dec 3, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

83 84 Next >

Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board? ↗

February 21, 2025

JPMorgan sees Gilead well-positioned due to its strong HIV drug portfolio and disciplined expense management.

Via Stocktwits

Large Cap Biopharmaceutical Metrics And Performance Q1 2025 ↗

February 20, 2025

Tariffs could have big impact on earnings in 2025.

Via Talk Markets

Topics Stocks / Equities

Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer ↗

February 19, 2025

Bristol Myers' Opdivo improved overall survival in resectable NSCLC, per final Phase 3 data. The study confirms its benefit when combined with chemotherapy.

Via Benzinga

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields ↗

February 19, 2025

Via Benzinga

Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer

February 19, 2025

From Bristol Myers Squibb

Via Business Wire

Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich ↗

February 18, 2025

Robert Reich has termed Donald Trump's taxation policies as an "absolutely shameless giveaway," that could shoot up deficit to $4.6 trillion.

Via Benzinga

Topics Government

Nuclear Power Is Solving the World’s Looming Energy Crisis ↗

February 16, 2025

Trump’s unpredictable tariff strategy is creating major market shifts. Discover how to read his next moves and uncover hidden investment opportunities before they take off.

Via InvestorPlace

Topics Government World Trade

New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis

February 16, 2025

From Bristol Myers Squibb

Via Business Wire

My “Two-Step” Plan for Surviving Shaky Markets – and Coming Out Ahead ↗

February 15, 2025

Trump’s unpredictable tariff strategy is creating major market shifts. Discover how to read his next moves and uncover hidden investment opportunities before they take off.

Via InvestorPlace

Topics Government World Trade

Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial

February 13, 2025

From Bristol Myers Squibb

Via Business Wire

How to Read Trump’s Tariff Playbook – and Prepare for His Next Moves ↗

February 13, 2025

Trump’s unpredictable tariff strategy is creating major market shifts. Discover how to read his next moves and uncover hidden investment opportunities before they take off.

Via InvestorPlace

Topics Government World Trade

Earnings To Watch: Zoetis (ZTS) Reports Q4 Results Tomorrow

February 12, 2025

Animal health company Zoetis (NYSE:ZTS) will be reporting results tomorrow before market open. Here’s what to look for.

Via StockStory

Organon (OGN) Q4 Earnings Report Preview: What To Look For

February 12, 2025

Pharmaceutical company Organon (NYSE:OGN) will be reporting earnings tomorrow before market hours. Here’s what investors should know.

Via StockStory

Gapping S&P500 stocks in Monday's session ↗

February 10, 2025

Let's have a look at the S&P500 gap up and gap down stocks in today's session.

Via Chartmill

What's Going On With Bristol Myers Squibb Stock On Monday? ↗

February 10, 2025

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand its reach in B-cell cancers.

Via Benzinga

Royalty Pharma Earnings: What To Look For From RPRX

February 10, 2025

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting earnings tomorrow morning. Here’s what to look for.

Via StockStory

Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma

February 10, 2025

From Bristol Myers Squibb

Via Business Wire

MarketBeat Week in Review – 02/03 - 02/07

February 08, 2025

Despite a Monday sell-off, stocks ended the week higher, and there's evidence that sector rotation is underway; next week's read of inflation may move markets.

Via MarketBeat

Topics Artificial Intelligence Economy World Trade

Weak Guidance from Bristol-Myers Could Be Creating an Opportunity

February 07, 2025

Bristol-Myers stock fell after earnings, but analysts remain bullish which suggests that any dip in the stock may create a buying opportunity

Via MarketBeat

US Stocks Likely To Open On A Mixed Note: Amazon, Pinterest, Take-Two Among Stocks To Watch ↗

February 07, 2025

U.S. stocks could open mixed on Friday. Newell Brands, Flowers Foods, and Plains All American Pipeline to report earnings.

Via Benzinga

S&P 500 Gains For 3rd Session: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone ↗

February 07, 2025

Via Benzinga

Topics Stocks

Stocks Edge Higher, Bank Giants Rally, Palantir Skyrockets: What's Driving Markets Thursday? ↗

February 06, 2025

It's a mixed session on Wall Street, with major indices struggling for direction as investors hold their breath ahead of a key jobs report set for Friday morning. The S&P 500 and the Nasdaq 100 edged...

Via Benzinga

Topics Stocks

Bristol Myers Squibb (BMY) Q4 2024 Earnings Call Transcript ↗

February 06, 2025

BMY earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

Dow Dips 150 Points; Bristol Myers Squibb Issues Weak Outlook ↗

February 06, 2025

Via Benzinga

Topics Stocks

Bristol Myers Squibb Tops Q4 Estimates ↗

February 06, 2025

Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.

Via The Motley Fool

Bristol-Myers Squibb Stock Slides On Weak 2025 Outlook, Retail Steps In To Buy The Dip ↗

February 06, 2025

The company announced plans to generate $2 billion in annual cost savings by the end of 2027.

Via Stocktwits

Wondering what's happening in today's S&P500 pre-market session? ↗

February 06, 2025

Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top S&P500 gainers and losers in today's pre-market session.

Via Chartmill

Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost Cuts ↗

February 06, 2025

Bristol Myers Squibb beat Q4 estimates with $12.34 billion revenue and $1.67 EPS. 2025 guidance lags expectations amid generic headwinds and cost-saving plans.

Via Benzinga

Bristol Myers Wallops Fourth-Quarter Earnings Views. But Shares Plummet 5%. ↗

February 06, 2025

Bristol Myers Squibb stock tumbled Thursday on a light outlook for 2025 following a strong fourth-quarter report.

Via Investor's Business Daily

Bristol-Myers Squibb (NYSE:BMY) Posts Better-Than-Expected Sales In Q4 But Full-Year Sales Guidance Misses Expectations

February 06, 2025

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q4 CY2024, with sales up 7.5% year on year to $12.34 billion. On the other hand, the company’s...

Via StockStory

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

83 84 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.